tbuckley/cabot-search huggingface dataset:
The RNA binding protein HuR/ELAV1 regulates the estrogen receptor and epidermal growth factor receptor beta expression in BT 474 cells.
Authors: LA Licata, C Hostetter, JC Keen
Journal: Cancer Research (2009)

Abstract Abstract #3076 The RNA binding protein HuR has been shown to increase the mRNA stability of the majority of transcripts to which in binds. Recent data has linked the cytoplasmic distribution of HuR to the tumorigenesis process in many cancer types. HuR levels were found to be higher in more metastatic, higher grade breast tumors, suggesting that it may play a role for stabilization of growth-promoting transcripts in breast cancer cells. Previously, our lab has shown that the DNA methyltransferase inhibitor 5-aza- 2'deoxycytidine (AZA) and histone deacetylase inhibitor Trichostatin A (TSA) decreased the cytoplasmic accumulation of HuR in MDA-MB-231 and MCF-7 cells. Therefore, to examine the role of HuR in the more tumorigenic, estrogen receptor (ER) positive, Tamoxifen resistant BT 474 cells were treated with AZA/TSA or siRNA probes specifically targeting HuR expression. The BT 474 cells had a baseline increase in the cytoplasmic distribution of HuR as compared to MCF-7 and MDA-MB-231 cells. The half-life of ER mRNA was also increased. Following AZA/TSA treatment for 24-96 hours, cytoplasmic HuR was noticeably lower after 48 hours of treatment. Subsequent mRNA levels of both ER and epidermal growth factor beta (erbB2/HER2) were also found to drop with treatment. siRNA inhibition of HuR had a similar effect on the mRNA levels. Biotin pulldown assays using probes specific for the ER 3' UTR showed HuR binding was decreased with AZA/TSA treatment. These were similar findings as previously reported in MCF7 cells. Since ER and erbB2 are central to hormonal therapy, Tamoxifen sensitivity was assessed using BT 474 cells transfected with siRNA probes specifically targeting HuR expression. Cellular viability following Tamoxifen treatment was significantly decreased when HuR expression was inhibited and Tamoxifen sensitivity was restored. Similar studies investigating the role of HuR in herceptin resistance are currently ongoing. Taken together, our data suggests that HuR plays a key role in both de novo and acquired Tamoxifen resistance. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3076.
SAT0415 Effects of Intra-Articular Clodronate in the Treatment of Knee Osteoarthritis: Results of A Double-Blind, Randomised Placebo-Controlled Trial
Authors: G. Orsolini, L. Idolazzi, M. Rossini, O. Viapiana, E. Fracassi, M. Povino, M. Risoli, D. Gatti, S. Adami
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Recently data strengthens the concept that treatment with bisphosphonates may be associated with beneficial symptomatic effects and perhaps structural benefits in people with osteoarthritis. <h3>Objectives</h3> Aim of this study was to evaluate the efficacy and tolerability of intra-articular (IA) clodronate, compared to saline solution, in patients with symptomatic knee osteoarthritis (KOA). <h3>Methods</h3> In this double blind phase 3 randomized clinical trial patients were randomized to receive once weekly IA injection of 2 mg clodronate or placebo for 4 weeks with 14 weeks of follow-up. The primary objective was the sum of spontaneous, on passive movement and at digital pressing pain relief assessed by visual analogue score (VAS) of 0-100. Improving in Western Ontario MacMaster (WOMAC) scale, Lequesne Index, consumption of acetaminophen, and physician or patient overall judgment were secondary objectives. <h3>Results</h3> Study population included 80 patients, 67 women and 13 men aged 66±6 (SD) years. A significant improvement for all efficacy parameters was observed at all-time points in both groups. A significant difference in favor to clodronate in VAS for pain was observed 3 and 5 weeks after the last injection. The improvements in Lequesne index, global KOA evaluation from both patients and investigators, and the WOMAC pain subscale were significantly greater in clodronate group 3-5 weeks after the last injection. The proportion of patients that did not require acetaminophen was significantly greater in the clodronate group. <h3>Conclusions</h3> IA 2 mg clodronate is safe and is associated with small and transient symptomatic and functional benefits in KOA patients in addition to those seen with saline solution. The opportunity to further investigate this therapeutic option is questionable. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4532
Abstract 4453: Smoking characteristics, intention to quit, and nicotine dependence in patients with head and neck cancer
Authors: Michael S.C. Conlon, Deborah P. Saunders, Margaret L. Meigs, Justin A. Allemano, Mary A. Bewick
Journal: Cancer Research (2012)

Abstract There are high rates of smoking among head and neck cancer patients, and successful smoking cessation may offer a treatment and survival benefit for these patients. This prospective study was designed to assess baseline smoking characteristics, and intention to quit in a cohort of patients with head and neck cancer. All patients attended the dental oncology clinic within the regional cancer centre for assessments before, during, and after primary treatment. Primary treatment included one or more of radiation therapy, chemotherapy, or surgery. Participation in this study was offered to ever smokers (defined as having smoked at least 100 cigarettes in their lifetime), and involved completing a questionnaire that assessed baseline smoking related behaviours, including nicotine dependence using the Fagerstrom Test for Nicotine Dependence (FTND), and intention to quit smoking. Patients were asked for consent to provide a saliva sample for genetic analyses and for future contact to assess smoking cessation and other health-related outcomes. Personalised counselling about smoking cessation, by trained staff, was also offered. One hundred and eleven consecutive patients have agreed to participate. Most (77 %) are male, with a median age of 65 years (range 36-92 years). Participants reported a median of 37 pack-years of smoking, and 43% were nicotine dependent (FTND score indicating high or very highly dependent). Nicotine dependence level was significantly associated with smoking status at enrolment, with current smokers more likely to report significantly higher nicotine dependence levels than those who were not smoking (p=0.03). While 96% (n=104) of the participants had previously attempted smoking cessation, 35% (n=39) were current smokers at study enrolment. Most of the current smokers (80%) were interested in quitting smoking and in receiving personalized counselling for cessation. This study demonstrates the need to support cessation efforts in this population of cancer patients, and highlights the role of nicotine dependence and smoking behaviour. Future research into smoking cessation methods, including the role of genetic variants in nicotine dependence and cessation, may help us better address smoking behaviours in cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4453. doi:1538-7445.AM2012-4453
P135 DEPLETION OF H2O2 BY CATALASE INDUCES MYELOID-DERIVED SUPPRESSOR CELLS – A NOVEL MECHANISM OF IMMUNE-REGULATION BY HEPATIC STELLATE CELLS
Authors: Y.J. Resheq, K.-K. Li, S. Wards, A. Wilhelm, A. Garg, S.M. Curbishley, H.W. Zimmermann, R. Jitschin, D. Mougiakakos, C. Weston, D.H. Adams
Journal: Journal of Hepatology (2014)
Abstract 3983: MiR-31 isoforms differentially regulate expression of dicer in cancer cells
Authors: Yu-Tzu Chan, You-Chin Lin, Ruey-Jen Lin, Huan-Hsien Kuo, Kuo Ping Chiu, Alice L. Yu
Journal: Cancer Research (2011)

Abstract MicroRNAs (miRNAs) are a group of small non-coding RNAs involved in several important biological processes. Recent studies have implied that imprecise cleavage of primary or precursor RNA by Drosha or Dicer respectively could produce miRNAs with variations at 5’-and/or 3’-ends, which were termed “isomiR”. The existence of isomiRs may increase the complexity of miRNA biology, although their functions have not been explored. This is further complicated by the observation of variations in the population of isomer for a given miRNA among different species as well as among different types of cells within the same species (human cells), which raises the issue whether these isomers might exert differential effects on target gene regulation. Here, we utilized three miR-31 isoforms (miR-31-H, miR-31-P, and miR-31-M) which differ from each other only slightly in their sequences at both ends, to compare their capacity to regulate a predicted target, Dicer. Interestingly, we found only miR-31-P was able to directly repress Dicer expression in both breast cancer MCF-7 cells and lung cancer A549 cells, resulting in their enhanced sensitivity to cisplatin, which is known to be associated with Dicer knockdown. In line with this, the amount of miR-31-P bound to the RNA-induced silencing complex (RISC) was greater than that of miR-31-H and -M by RNA-CHIP analysis. Furthermore, evaluation of other known miR-31 target genes showed that expression of some target genes was indeed differentially regulated by miR-31 isoforms. Our findings not only revealed Dicer to be a direct target of miR-31, but also demonstrated the disparate functions of isomiRs for the fist time, providing a novel functional mechanism of fine-tuning of gene expression by miRNAs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3983. doi:10.1158/1538-7445.AM2011-3983
Illustration of Protein Loss From the Stomach by Using SPECT/CT
Authors: Shigeaki Higashiyama, Joji Kawabe, Atsushi Yoshida, Kohei Kotani, Susumu Shiomi
Journal: Clinical Nuclear Medicine (2014)

We report a 47-year-old man in whom 99mTc human serum albumin diethylene-triamine-pentaacetic acid protein-losing scintigraphy, performed with SPECT/CT, was useful for diagnosing Ménétrier disease. Planar images taken 1 and 3 hours after radioactive isotope injection yielded a suspicion that the stomach was the site of protein loss in this case. However, the protein loss from the stomach was precisely diagnosed after SPECT/CT was performed; this helped to diagnose Ménétrier disease.
Case 28-2009
Authors: Bimalangshu R. Dey, Thomas R. Spitzer, Robert P. Hasserjian
Journal: New England Journal of Medicine (2009)

A 68-year-old man was seen in the cancer center of this hospital because of fatigue, cough, and peripheral-blood monocytosis. Seven weeks earlier, fatigue, cough, and urinary symptoms developed; a diagnosis of a urinary tract infection was made, and treatment with antibiotics was begun. A complete blood count disclosed leukocytosis with atypical cells; subsequent flow cytometry revealed myeloid blasts. A diagnostic procedure was performed, and a management decision was made.
SAT0001 Multicentric Study of Cognitive Impairment in Sle: the Ecles Study: Table 1
Authors: A. D'Amico, L.S. Galván, J. Romero, V. Arturi, M.V. Collado, G. Gόmez, A. Spindler, G. Rojas, F. Fillippin, L. Vita, R. Cόrdova, A. Panόpulos, M.C. Khoury, M.A. García, G. Rodriguez, A. Carosella, C. Moreno, J. Sarano, J.C. Barreira
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patients with systemic lupus erythematosus (SLE) have an increased risk of cognitive impairment (CI) of 39-46% compared to healthy individuals and it may be due to the disease, its complications, its therapy or associated comorbidities. <h3>Objectives</h3> To determine the frequency and characteristics of CI in lupus patients without known previous NP events. <h3>Methods</h3> Patients aged 16-51 fulfilling 1997 criteria for SLE enrolled from 06/2012 to 07/2013 were included. The ACR battery was used to determine CI, the Cognitive Symptoms Inventory (CSI) and Beck depression were also assessed. CI was defined as ≤2 standard deviations compared to the general population in at least one test. It was considered a focal (CIf) involvement if it affected one or more measures of a single domain and multifocal (CIm) if 2 or more domains were affected. To compare proportions, Fisher9s exact test was used and to compare numerical variables, Kruskal-Wallis. A value of p&lt;0,05 was considered significant. <h3>Results</h3> Eighty-six patients were evaluated, 94% were female, median age 36 years (16-51), 90% were Caucasian, 8% mestizos and 1% Amerindian. Eighty % had high school. Median SLEDAI was 2.5% (0-24) and median SLICC 0 (0-8).CI was found in 65% of patients (56/86), focal (CIf) 32.5% (28/56) and multifocal (CIm) in the same rate. The affected domains were: memory 45%, executive functions 30%, attention 29% and language 4.6%.Depression was detected in 48% of patients. Risk factors were analyzed for the different groups: without CI (n=30), CIf (n=28) and CIm (n=28) although we found no statistically significant difference except for ethnicity (table 1). Non-Caucasian patients had a higher median SLEDAI of 8 (2-24), median duration of disease 10 (1-31), although CI was not associated with the number of years of education. <h3>Conclusions</h3> A high frequency of CI was found in patients with SLE, non-Caucasian had higher CI with significant differences. Patients with CI had a longer history of the disease without reaching statistical significance, and it was not related to the number of years of education or with rates of depression. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2616
AUTOMATED QUANTIFICATION OF RIGHT VENTRICULAR SIZE AND SYSTOLIC FUNCTION BY REAL-TIME VOLUME TRANS-THORACIC ECHOCARDIOGRAPHY: COMPARISON WITH CARDIAC MAGNETIC RESONANCE IMAGING
Authors: Xiao Zhou, Zhen Qian, Shizhen Liu, Theresa Green, Scott Edwards, Sarah Rinehart, Venkateshwar Polsani, Mani Vannan
Journal: Journal of the American College of Cardiology (2015)
Abstract 190: p53 target gene expression, DNA hypomethylation, and clinical response in MDS patients undergoing decitabine therapy
Authors: Petra A. Link, Wa Zhang, David Gold, Meir Wetzler, Maria R. Baer, Adam R. Karpf
Journal: Cancer Research (2010)

Abstract The myelodysplastic syndromes (MDS) are a heterogeneous group of blood disorders characterized by peripheral cytopenias, a cellular bone marrow with dysplasia and increased intramedullary apoptosis, and are associated with risk of progression to acute myelogenous leukemia (AML). MDS are often fatal due to complications from cytopenias and/or progression to AML. DNA methyltransferase inhibitors (DNMTi), including 5-azacytidine and 5-aza-2’-deoxycytidine (decitabine) have recently assumed a major role in the clinical management of MDS, and are two of only three FDA-approved treatments for these disorders. The mechanistic basis for the activity of DNMTi in MDS is unclear. We recently reported that decitabine treatment induces the expression of p53-inducible ribonucleotide reductase p53R2/RRM2B in tumor cell lines and MDS patient bone marrow (Link et al., Cancer Research 68; 9358-9366, 2008). Importantly, p53R2 induction was independent of DNA hypomethylation at its promoter region, and the level of p53R2 induction correlated with clinical response in a cohort of 13 patients. These data suggest that important pharmacodynamic responses to DNMTi may be associated with DNA damage and/or p53 activation. To better understand the overall nature of the molecular responses occurring in the bone marrow of MDS patients treated with decitabine, in the current study we examined a variety of pharmacodynamic endpoints including: p53 target gene expression, global DNA methylation, tumor antigen gene expression and methylation, and tumor suppressor gene expression. Specifically, we measured the expression of three classical p53 target genes (p21, GADD45-α, NOXA), LINE-1 repetitive element methylation, the expression and methylation of cancer-germline (CG) antigens including MAGE-A1, NY-ESO-1, XAGE-1, and CTCFL/BORIS, and the expression of the tumor suppressor genes (TSGs) p15INK4b and PDLIM4. Our data reveal that decitabine treatment causes robust induction of p53 target genes in MDS patient bone marrow, which coincides with LINE-1 hypomethylation and clinical responses. In contrast, while CG antigen genes showed some evidence for DNA hypomethylation post-therapy, this did not coincide with CG antigen gene induction. Surprisingly, TSGs were also not induced by decitabine therapy in MDS patient bone marrow. Ongoing studies seek to define p53 mutational status in MDS patients and to determine how this relates to p53 target gene induction and/or clinical response. In summary, our data reveal a connection between p53 target gene activation, global DNA hypomethylation, and clinical response in MDS patients undergoing decitabine therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 190.
Cancer Risks in Patients with Chronic Lymphocytic Thyroiditis
Authors: Lars-Erik Holm, Henric Blomgren, Torsten Löwhagen
Journal: New England Journal of Medicine (1985)

The incidence of malignant tumors and leukemia was analyzed in 829 patients with chronic lymphocytic thyroiditis and in 829 individually age-matched and sex-matched patients with colloid goiter. Diagnoses were based on cytologic studies of specimens obtained by fine-needle aspiration biopsy. The patients were examined between 1959 and 1978 and were followed in the Swedish Cancer Register between 1959 and 1981. There was no increased risk for the total number of tumors in the thyroiditis group (53 observed vs. 52.7 expected) or in the colloid-goiter group (40 vs. 53.2, respectively; P not significant). There were six lung cancers in the thyroiditis group (2.9 expected, P not significant), and one in the group with colloid goiter. Patients with thyroiditis had an increased risk of myeloproliferative and lymphoproliferative neoplasms (12 observed vs. 3.0 expected, P less than 0.001). The risk of malignant thyroid lymphoma was greatly increased, with an estimated relative risk of 67 (4 observed vs. 0.06 expected, P less than 0.000001). There was no increased risk for any type of tumor among patients with colloid goiter.
Enhancement of Clinical Radioimmunotherapy for Cancer and the Role of Cytokines
Authors: Sally J. DeNardo, Gerald L. DeNardo, Carol M. Richman
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Enhancement of Clinical Radioimmunotherapy for Cancer and the Role of Cytokines Get access Sally J. DeNardo, Sally J. DeNardo Search for other works by this author on: Oxford Academic PubMed Google Scholar Gerald L. DeNardo, Gerald L. DeNardo Search for other works by this author on: Oxford Academic PubMed Google Scholar Carol M. Richman Carol M. Richman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 6, 18 March 1992, Pages 374–375, https://doi.org/10.1093/jnci/84.6.374 Published: 18 March 1992 Article history Received: 19 February 1992 Accepted: 19 February 1992 Published: 18 March 1992
SP0144 Overview of Future Eular Projects in Musculosketal Imaging
Authors: E. Naredo
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> The aims of the EULAR Standing Committee on Musculoskeletal Imaging (SCMI) committee are to promote Education and research in imaging modalities as well as improve patient care through the appropriate use of imaging modalities. The committee is composed by delegates coming from member countries of EULAR, a representative of EUMEUNET and several co-opted members with particular interest in imaging both for research and education purposes. This lecture offers an overview of future EULAR projects in musculosketal imaging under the umbrella of the committee. <h3>Disclosure of Interest</h3> E. Naredo Grant/Research support from: UCB and MSD, Consultant for: Abbvie, Roche Farma, Bristol-Myers Squibb, Pfizer, UCB, General Electric Healthcare, and Esaote <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6147
THE PSYCHIATRIST AND THE PSYCHOTIC PSYCHOPATH
Authors: BERNARD A. CRUVANT, LEON YOCHELSON
Journal: American Journal of Psychiatry (1950)

We have been, for some time, perturbed by the extraordinary looseness with which the term "psychosis with psychopathic personality" seems to be applied. A study of written opinions solicited from a number of colleagues when contrasted with a number of cases so diagnosed disclosed discrepancies between theory and practice. It is our opinion that these discrepancies are due to factors operating within the psychiatrist in his role of "participant observer." This problem of the psychiatrist is intensified by the present nosological confusion. We believe that it is more handicapping than helpful at this time to consider "psychopathic personality" and "psychosis with psychopathic personality" as distinct entities rather than as varieties of the conventional neuroses and psychoses.
P01.18 * AUTOCRINE VEGFC-VEGFR2 SIGNALING IS OF IMPORTANCE FOR THE GROWTH OF GLIOBLASTOMA MULTIFORME
Authors: S. R. Michaelsen, M. K. Nedergaard, M. Villingshoj, P. Pedersen, M. Stockhausen, H. S. Poulsen
Journal: Neuro-Oncology (2014)

BACKGROUND: Recent research shows that the angiogenic mediator Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is expressed in Glioblastoma Multiforme (GBM) cells and that inhibition of VEGFR2 results in reduced growth of GBM cells. Although autocrine VEGFA-VEGFR2 signaling has been identified in these GBM cells, VEGFA inhibition has very limited effect on growth in the cells, indicating that activation of VEGFR2 in GBM cells not solely is dependent on VEGFA. METHODS: Material consisted of 5 GBM cell cultures established under stem cell conditions and tumors from 18 GBM patients. Angiogenesis-related genes were deregulated using SU1498, recombinant VEGFA-165 and VEGFC protein and VEGFC specific siRNA and a corresponding control. Cell viability was measured using MTT assay, mRNA expression by Q-PCR, protein expression by western blotting and tumor growth by bioluminescence imaging. RESULTS: Examination of a panel of GBM cell cultures identified one culture positive for VEGFR2, while the receptor was undetectable in the remaining cultures. As shown by others, we found that inhibition of receptor phosphorylation by SU1498 resulted in significantly reduced proliferation of the VEGFR2-positive cells. Although VEGFR2 phoshorylation could be stimulated by recombinant VEGFA, inhibition of the VEGFA expressed by the cells using Bevacizumab only had minimal effect on proliferation. Examination of the expression of a range of genes revealed that the VEGFR2 positive cells also were positive for the VEGF variant VEGFC. Addition of recombinant VEGFC protein to the VEGFR2 positive cells resulted in VEGFR2 phosphorylation, while inhibition of VEGFC using specific siRNA constructs resulted in significantly reduced in vitro growth of VEGFR2 positive cells. Moreover, when transplanted as orthotopic brain tumors significantly reduced tumor growth was seen for VEGFC siRNA transfected cells as compared to control cells. In parallel, the median survival was increased from 34 days in mice injected with control cells to 55 days in mice injected with VEGFC siRNA transfected cells. Further, to establish the relevance of VEGFC in GBM patient tumors in general, we measured the VEGFC mRNA level in 18 GBM tumors. Although the level was varying, all examined tumors were positive for VEGFC expression. CONCLUSION: GBM cells can in addition to VEGFA also be dependent on VEGFC for VEGFR2 activation, cell viability and tumor growth.